China Ultrasound Domestic Substitution, Procurement Policy, and the Mindray-Led Order: A Focus Report on the World's Most Distinct Ultrasound Competitive System, 2024A-2035E

This report examines China's diagnostic ultrasound market as a parallel competitive system. Built on the analyst's ultrasound core model and the Markintel® methodology, it covers systems, service and AI revenue from 2024 through 2035, with a dated refresh through early July 2026.

In our view, commercial strategy in China is procurement strategy. Shipments expand much faster than hardware revenue, and public procurement rules decide who captures what remains. Mindray is the clearest beneficiary of the resulting substitution wave.

Key Questions Answered

• Why does shipment growth outpace systems revenue, and what does that mean for cost structure?
• How are volume-based procurement, the 2026 renewal phase and made-in-China standards changing tender eligibility?
• How far has domestic substitution moved, and where can multinationals still defend position?
• Where will AI and service revenue be earned in a procurement-led market?

Market Snapshot

The model covers five hardware segments, from premium carts to handheld/POCUS, plus service, core AI recurring revenue and an AI value-pool bridge. Compact and portable consoles become the revenue center of gravity by 2035 and handheld/POCUS grows fastest, while value carts stall under tender pressure. Above-hardware revenue stays thinner than the global norm.

Key Market Trends

1. Access grows faster than dollars. Falling blended pricing gives back much of the placement gain, so size plans against net revenue.
2. Procurement gains guardrails. Volume-based procurement adds anchor-price mechanisms, and equipment renewal enters a stricter, phased 2026 cycle.
3. Localization becomes the admission ticket. Codified domestic-product standards make made-in-China status a condition of access to the public channel.
4. AI is bought on policy's terms. Primary-care AI goals and early per-study reimbursement pilots favor cloud and remote-review economics.

Competitive Structure

The report analyzes a Mindray-led order across four linked layers: domestic OEM scale, local AI and software, component sovereignty, and exports. It tracks domestic gains in public-tender value, profiles Mindray, SonoScape, United Imaging Healthcare and smaller local players, and reviews how GE HealthCare, Philips and other multinationals are localizing or narrowing focus.

What's Inside

Systems and ecosystem layers: Revenue, shipments and installed base by hardware segment, the systems growth bridge and the AI value-pool bridge.

Policy architecture: Procurement, renewal, domestic preference, trade measures and NMPA regulation, with a 2024-2026 timeline.

Market structure views: End-market, clinical application, purchase model and operating model mixes.

Refresh and actions: A dated freshness log, recommendations by participant type and 12-24-month signals.

Who Should Read This Report

• Investors underwriting China medtech exposure
• Multinational strategy teams weighing localization
• Domestic ultrasound vendors and component suppliers
• AI developers targeting county and primary-care deployment
• Export planners assessing China-rooted competition in third markets

Why This Report

The report treats China as a strategic theater of its own rather than a regional footnote, ties every baseline to the analyst's ultrasound core model, and logs later developments separately so readers see what changed.